Advertisement Cytokinetics starts ALS drug Phase II second cohort study - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Cytokinetics starts ALS drug Phase II second cohort study

Cytokinetics has started Phase II trial's second cohort study of CK-2017357 to treat amyotrophic lateral sclerosis (ALS).

CK-2017357 is a skeletal muscle troponin activator which increases its sensitivity to calcium and delays the onset and reduces the degree of muscle fatigue.

The double-blind, placebo-controlled, randomized, safety and tolerability study of CK-2017357 is designed to enroll ALS patients who are also receiving riluzole.

The company is planning to enroll 24 patients from US study centers.

The primary objective of the trial is to evaluate the safety and tolerability of CK-2017357, after multiple oral doses to steady state plasma concentrations, in patients with ALS who are also receiving riluzole.

The secondary objective is to assess the ALS Functional Rating Scale-revised (ALSFRS-R), other measures of pulmonary function, muscle strength and fatigue, and physician and patient global assessments in these patients while receiving two weeks of treatment with CK-2017357 at the indicated doses or placebo.